Literature DB >> 15100107

False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.

Sendhil Kumar Cheran1, Nathan D Nielsen, Edward F Patz.   

Abstract

OBJECTIVE: The aim of this study was to determine the stage and outcome of patients with primary lung tumors who had a negative finding on a FDG positron emission tomography (PET) study at the time of diagnosis.
MATERIALS AND METHODS: A total of 3912 patients between November 1994 and August 2002 underwent thoracic or whole-body PET performed at our institution for evaluation of a pulmonary abnormality suspicious for lung cancer. We identified 20 patients with a biopsy-proven primary lung tumor and a negative PET study at the time of presentation. Surgical, pathologic, radiographic imaging, and clinical follow-up information were reviewed to confirm the histology, stage, and outcome.
RESULTS: Tumor histology included adenocarcinoma (n = 7, 35%), bronchioalveolar cell carcinoma (n = 6, 30%), carcinoid (n = 3, 15%), squamous cell carcinoma (n = 2, 10%), otherwise unspecified non-small cell lung cancer (n = 1, 5%), and sarcomatoid neoplasm (n = 1, 5%). One patient with bronchioalveolar cell carcinoma had multifocal stage IV disease, and all other patients were stage IA (n = 14, 70%) or stage IB (n = 5, 25%). Eighteen (90%) of the 20 patients underwent curative surgical resection. No patient is known to have tumor recurrence after resection, and three (17%) of the 18 patients are known to be living and free of disease 5 years after surgery.
CONCLUSION: With the exception of bronchioalveolar cell carcinoma and carcinoid, newly diagnosed lung cancers with negative PET findings are usually early-stage diseases and are associated with a favorable prognosis, suggesting that indeterminate pulmonary nodules, which are PET-negative, can be managed conservatively with serial radiographic studies to monitor for signs of growth. These findings warrant further study and should be confirmed with sufficient follow-up in a large cohort of patients with PET-negative lung lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100107     DOI: 10.2214/ajr.182.5.1821129

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  29 in total

Review 1.  The pulmonary nodule: clinical and radiological characteristics affecting a diagnosis of malignancy.

Authors:  L Cardinale; F Ardissone; S Novello; M Busso; F Solitro; M Longo; D Sardo; M Giors; C Fava
Journal:  Radiol Med       Date:  2009-05-29       Impact factor: 3.469

2.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

3.  Apparent diffusion coefficient values of diffusion-weighted imaging for distinguishing focal pulmonary lesions and characterizing the subtype of lung cancer: a meta-analysis.

Authors:  Guohua Shen; Zhiyun Jia; Houfu Deng
Journal:  Eur Radiol       Date:  2015-05-24       Impact factor: 5.315

4.  Comparing diffusion-weighted imaging and positron emission tomography for pulmonary nodules measuring from 1 to 3 cm in size.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-02-13       Impact factor: 2.549

5.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

6.  Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.

Authors:  Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

7.  A case of malignant peritoneal mesothelioma revealed with limitation of PET-CT in the diagnosis of thoracic metastasis.

Authors:  Takeshi Saraya; Takuma Yokoyama; Haruyuki Ishii; Yasutaka Tanaka; Naoki Tsujimoto; Yukari Ogawa; Erei Sohara; Akira Nakajima; Toshiya Inui; Hiraoka Sayuki; Masachika Fujiwara; Teruaki Oka; Riken Kawachi; Tomoyuki Goya; Hajime Takizawa; Hajime Goto
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

8.  Dynamic CT of solitary pulmonary nodules: comparison of contrast medium distribution characteristic of malignant and benign lesions.

Authors:  X-D Ye; J-D Ye; Z Yuan; W-T Li; X-S Xiao
Journal:  Clin Transl Oncol       Date:  2013-04-19       Impact factor: 3.405

9.  Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT.

Authors:  Klaus Strobel; Stephan K Haerle; Sandro J Stoeckli; Madeleine Schrank; Jan D Soyka; Patrick Veit-Haibach; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-10       Impact factor: 9.236

10.  Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.

Authors:  Kotaro Higashi; Tsutomu Sakuma; Kengo Ito; Seiji Niho; Yoshimichi Ueda; Takeshi Kobayashi; Ryuzo Sekiguchi; Tomoko Takahashi; Takashi Kato; Hisao Tonami
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.